- Target disease: Visceral leishmaniasis
- Main Partners (since project start): AbbVie, USA; BioAster, France; Centre for Drug Candidate Optimisation, Monash University, Australia; Epichem, Australia; Eurofins CEREP, France; Eurofins Pharma Discovery Services (formerly Eurofins Panlabs), USA; Griffith Institute for Drug Discovery (GRIDD), Griffith University, Australia; Laboratory of Microbiology, Parasitology and Hygiene, University of Antwerp, Belgium; London School of Hygiene and Tropical Medicine, UK; WuXi AppTech, China.
- Project start: 2017
- Funding (since project start): Department for International Development (DFID), UK; Dutch Ministry of Foreign Affairs (DGIS), The Netherlands; Federal Ministry of Education and Research (BMBF through KfW), Germany; Médecins Sans Frontières/Doctors without Borders, International; Swiss Agency for Development and Cooperation (SDC), Switzerland.
Following proof-of-principle with the 205 series for visceral leishmaniasis, compounds from this series have shown a 100% parasite load reduction in liver and spleen in a visceral leishmaniasis murine model. Further characterization of this series is ongoing.
Lead compound DNDI-6588 showed great efficacy in vivo in both mouse and hamster models for visceral leishmaniasis. Additional 205-series compounds having similar or improved profiles have been added to the candidate shortlist and are currently being assessed.
Over 400 compounds have been synthesized to date in this lead optimization programme for Chagas disease and leishmaniasis.
Last update: February 2019